Share-based Payment Arrangement, Expense of Unicycive Therapeutics, Inc. from 31 Dec 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Unicycive Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2020 to 30 Sep 2025.
  • Unicycive Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $729,000, a 20% increase year-over-year.
  • Unicycive Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $2,445,000, a 5.5% increase year-over-year.
  • Unicycive Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $2,350,000, a 33% increase from 2023.
  • Unicycive Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1,767,000, a 69% increase from 2022.
  • Unicycive Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $1,047,000, a 8.4% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Unicycive Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $2,445,000 $729,000 +$124,000 +20% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $2,321,000 $571,000 -$70,000 -11% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $2,391,000 $563,000 +$41,000 +7.9% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $2,350,000 $582,000 +$32,000 +5.8% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
Q3 2024 $2,318,000 $605,000 -$324,000 -35% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $2,642,000 $641,000 +$497,000 +345% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $2,145,000 $522,000 +$378,000 +262% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $1,767,000 $550,000 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q3 2023 $929,000 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $144,000 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $144,000 -$146,000 -50% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024 2024 Q1
Q1 2022 $290,000 +$88,000 +44% 01 Jan 2022 31 Mar 2022 10-Q 16 May 2023 2023 Q1
Q1 2021 $202,000 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1

Unicycive Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $2,350,000 +$583,000 +33% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 $1,767,000 +$720,000 +69% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 $1,047,000 +$81,000 +8.4% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
2021 $966,000 +$734,000 +316% 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
2020 $232,000 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.